Active substance
Results for the substance erdafitinib
4 results
About this active substance
Erdafitinib is a medication used to treat certain types of advanced or metastatic bladder cancer in patients with specific FGFR receptor mutations. It works by inhibiting the activity of this receptor, thus blocking the growth and multiplication of cancer cells.
Erdafitinib is administered orally as tablets, according to the oncologist's instructions. The dose is adjusted depending on the patient's response to treatment and any side effects.
Side effects may include eye disorders (blurred vision), increased phosphate levels in the blood, fatigue, nausea, diarrhea, or, rarely, severe allergic reactions. Careful monitoring is necessary throughout the treatment.
Erdafitinib is a modern option for patients with advanced bladder cancer, offering the chance to slow disease progression and improve quality of life.
Erdafitinib is administered orally as tablets, according to the oncologist's instructions. The dose is adjusted depending on the patient's response to treatment and any side effects.
Side effects may include eye disorders (blurred vision), increased phosphate levels in the blood, fatigue, nausea, diarrhea, or, rarely, severe allergic reactions. Careful monitoring is necessary throughout the treatment.
Erdafitinib is a modern option for patients with advanced bladder cancer, offering the chance to slow disease progression and improve quality of life.
-
-
BALVERSA 5mg film-coated tablets CILAG ORIGINAL MEDICINE
-
BALVERSA 3mg film-coated tablets CILAG ORIGINAL MEDICINE
-
BALVERSA 4mg film-coated tablets CILAG ORIGINAL MEDICINE